Innovative Cellular Therapeutics

Focus: Innovative Cellular Therapeutics is a newly founded (2024) biotech company focused on CAR-T cell therapies for hematologic and solid tumors, headquartered in Rockville, MD. The company is pre-revenue and operates at early clinical stage with a focused pipeline.

Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Innovative Cellular Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Innovative Cellular Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CD19CART

Leukemia, B-Cell

N/A

Clinical Trials (1)

NCT02813837Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

N/A

Help build intelligence for Innovative Cellular Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage entry point into a hot modality: CAR-T therapies remain high-value in oncology with multiple programs across leukemia, lymphoma, and solid tumors.
Ground-floor opportunity at a 2024-founded company with potential for rapid advancement and equity upside before funding/exit events.
Exposure to multi-indication pipeline including GUCY2C-targeted CAR-T for GI malignancies, an emerging approach with less competitive saturation.

Watch Out For

Pre-revenue biotech with no disclosed funding, cash position, or employee count—high execution and financing risk; company viability depends entirely on capital raises.
Zero current job openings and only 4 total clinical trials (mostly Phase 1) suggests minimal hiring activity and slower clinical pace than competitors; no revenue or regulatory catalysts in near term.

Generated by Claude from Innovative Cellular Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

gucy2c cart cells

Malignant Neoplasms of Digestive Organs

N/A

Clinical Trials (1)

NCT04780529CART Therapy in Digestive System Tumors

N/A

gucy2c cart cells

Malignant Neoplasms of Digestive Organs

Phase 1

Clinical Trials (1)

NCT04652219CART Therapy in GUCY2C-positive Digestive Tract Tumors

Phase 1

CD19 targeted chimeric antigen receptor T cells

Lymphoma

Phase 1/2

Clinical Trials (1)

NCT03118180CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline